In summary, we calculated PRS for evaluating AUD risk that worked cross populations based on our novel gene-based PRS framework. Not only our new framework outperformed the PRS calculated using all variants in AA, but also the genes included in calculating PRS showed enrichment for biological plausible processes and are potential targets for drug development, therefore, this novel framework demonstrates the utilities of PRS beyond disease risk evaluation to the identification of biological processes and drug targets, and shed light on the genetic mechanism of AUD.
